Journal of Parkinsons Disease

Papers
(The TQCC of Journal of Parkinsons Disease is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease105
The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease99
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects96
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 202089
The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease84
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline84
Barriers and Motivators to Engage in Exercise for Persons with Parkinson’s Disease74
Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C’s that Will Shape the Future of Telemedicine68
Young Onset Parkinson’s Disease: A Modern and Tailored Approach65
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop64
Parkinson’s Disease and the COVID-19 Pandemic63
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations58
Infection and Risk of Parkinson’s Disease56
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update50
LRRK2 and the Endolysosomal System in Parkinson’s Disease48
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead47
Parkinsonism as a Third Wave of the COVID-19 Pandemic?47
Preventing Parkinson’s Disease: An Environmental Agenda46
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease44
Deep Phenotyping of Parkinson’s Disease43
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update42
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis41
Digital Biomarkers of Mobility in Parkinson’s Disease During Daily Living41
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk40
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future39
Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes37
Management of Pain in Parkinson’s Disease37
Global Perspective on Telemedicine for Parkinson’s Disease36
Recommendations for Deep Brain Stimulation Device Management During a Pandemic36
Management of Orthostatic Hypotension in Parkinson’s Disease35
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?34
Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future33
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?33
Oral Dysbiosis and Inflammation in Parkinson’s Disease33
Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson’s Disease32
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study32
The Effects of Respiratory Training in Parkinson’s Disease: A Systematic Review31
Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review31
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective31
Gait Kinematic Parameters in Parkinson’s Disease: A Systematic Review31
Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts31
Digital Therapeutics in Parkinson’s Disease: Practical Applications and Future Potential31
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture30
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOV30
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)29
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study28
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial27
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results27
COVID-19 and Parkinson’s Disease: What Do We Know So Far?26
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations26
The Universal Prescription for Parkinson’s Disease: Exercise26
Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction26
Does Gut Microbiota Influence the Course of Parkinson’s Disease? A 3-Year Prospective Exploratory Study in de novo Patients26
COVID-19 and Parkinson’s Disease: Are We Dealing with Short-term Impacts or Something Worse?25
Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson’s Disease: A Randomized Controlled Trial25
The Human Hippocampus in Parkinson’s Disease: An Integrative Stereological and Proteomic Study24
Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond24
A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease24
Proposal for a Biologic Staging System of Parkinson’s Disease24
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions24
A Practical Approach to Early-Onset Parkinsonism23
Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease23
Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease23
Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson’s Disease Patients22
Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease22
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion22
Cannabis in Parkinson’s Disease: The Patients’ View22
Genetics of Progressive Supranuclear Palsy: A Review22
Animal Models of Parkinson’s Disease: Are They Useful or Not?22
Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson’s Disease21
ParkinSong: Outcomes of a 12-Month Controlled Trial of Therapeutic Singing Groups in Parkinson’s Disease21
Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinson’s Disease Patients21
Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study21
Personalized Care Management for Persons with Parkinson’s Disease20
Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson’s Disease20
COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?20
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease20
Sexual Dysfunction in Early-Onset Parkinson’s Disease: A Cross-Sectional, Multicenter Study20
Parkinson’s Disease in African Americans: A Review of the Current Literature19
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?19
Effects of Helicobacter pylori on Levodopa Pharmacokinetics19
Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations19
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota19
Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses18
T Lymphocytes in Parkinson’s Disease18
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials18
Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson’s Disease Living in the United Kingdom18
Clinical Relevance of Standardized Mobile Gait Tests. Reliability Analysis Between Gait Recordings at Hospital and Home in Parkinson’s Disease: A Pilot Study18
Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye18
Microglia in Parkinson’s Disease18
A Dual Centre Study of Pain in Parkinson’s Disease and Its Relationship with Other Non-Motor Symptoms18
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers17
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies17
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease17
Comprehensive Analysis of Brain Volume in REM Sleep Behavior Disorder with Mild Cognitive Impairment17
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population17
Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson’s Disease17
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson’s Disease: A Feasibility Study17
Effectiveness of Long-Term Physiotherapy in Parkinson’s Disease: A Systematic Review and Meta-Analysis17
A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model17
What People with Parkinson’s Disease Want17
Multimorbidity and Frailty: Tackling Complexity in Parkinson’s Disease17
Unhealthy Behaviours and Risk of Parkinson’s Disease: A Mendelian Randomisation Study16
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease16
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis16
A Long Way to Go: Patient Perspectives on Digital Health for Parkinson’s Disease16
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?16
Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations16
Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson’s Disease15
“How Long Can I Carry On?” The Need for Palliative Care in Parkinson’s Disease: A Qualitative Study from the Perspective of Bereaved Family Caregivers15
The Gut Mycobiome in Parkinson’s Disease15
Management of Sleep Disturbances in Parkinson’s Disease15
Non-Genetic Risk Factors for Parkinson’s Disease: An Overview of 46 Systematic Reviews15
An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function15
Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment15
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients14
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease14
The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson’s Disease14
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review14
Predictors of Conversion to α-Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder14
CLOVER-DBS: Algorithm-Guided Deep Brain Stimulation-Programming Based on External Sensor Feedback Evaluated in a Prospective, Randomized, Crossover, Double-Blind, Two-Center Study14
Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson’s Disease14
Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease14
Minority Enrollment in Parkinson’s Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric Symptoms14
A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care14
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes14
Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson’s Disease14
SNCA Hypomethylation in Rapid Eye Movement Sleep Behavior Disorder Is a Potential Biomarker for Parkinson’s Disease14
Clinical Progression of Parkinson’s Disease: Insights from the NINDS Common Data Elements13
Lipidomics Prediction of Parkinson’s Disease Severity: A Machine-Learning Analysis13
Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder13
Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson’s Disease?13
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease13
Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinson’s Disease: Beyond Gait Speed13
Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls13
Barriers to Accessing Healthcare Services for People with Parkinson’s Disease: A Scoping Review13
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease13
Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review12
Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective12
Melanopsin Cell Dysfunction is Involved in Sleep Disruption in Parkinson’s Disease12
Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson’s Disease by Autophagy Activation12
Worsened Parkinson’s Disease Progression: Impact of the COVID-19 Pandemic12
Recruitment for Remote Decentralized Studies in Parkinson’s Disease12
New Insights and Implications of Natural Killer Cells in Parkinson’s Disease12
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity12
How Time Rules: Diurnal Motor Patterns in de novo Parkinson’s Disease12
Diet Quality and Risk of Parkinson’s Disease: A Prospective Study and Meta-Analysis12
Dopamine Cell Therapy: From Cell Replacement to Circuitry Repair12
Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson’s Disease12
T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils12
The Associations Between Physical Activity, Sleep, and Mood with Pain in People with Parkinson’s Disease: An Observational Cross-Sectional Study11
Perturbation of in vivo Neural Activity Following α-Synuclein Seeding in the Olfactory Bulb11
High IQ in Early Adulthood Is Associated with Parkinson’s Disease11
Cognitive Function and Quality of Life in Parkinson’s Disease: A Cross-Sectional Study11
Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing11
Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson’s Disease in the ICICLE-PD Cohort11
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?11
Induction of Parkinsonian-Like Changes via Targeted Downregulation of Astrocytic Glutamate Transporter GLT-1 in the Striatum11
Irritable Bowel Syndrome and Risk of Parkinson’s Disease in Finland: A Nationwide Registry-Based Cohort Study11
NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench?11
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited11
Smartphones for Remote Symptom Monitoring of Parkinson’s Disease11
A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson’s Disease: A Qualitative Study11
Inflammatory Animal Models of Parkinson’s Disease11
Reaching and Grasping Movements in Parkinson’s Disease: A Review11
Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson’s Disease: A Regulatory Perspective11
Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men11
Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis10
Happiness: A Novel Outcome in Parkinson Studies?10
Subthalamic Stimulation for Camptocormia in Parkinson’s Disease: Association of Volume of Tissue Activated and Structural Connectivity with Clinical Effectiveness10
Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis10
Presence of Skin α-Synuclein Deposits Discriminates Parkinson’s Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome10
Management of Visual Dysfunction in Patients with Parkinson’s Disease10
Locus Coeruleus Pathology Indicates a Continuum of Lewy Body Dementia10
Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson’s Disease (1991–2010)10
Frequency of Depressive Disorders in Parkinson’s Disease: A Systematic Review and Meta-Analysis10
Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group10
Predictors of Pharyngeal Dysphagia in Patients with Parkinson’s Disease10
Unraveling Parkinson’s Disease Neurodegeneration: Does Aging Hold the Clues?10
Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry10
Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment10
Perceptions of Compensation Strategies for Gait Impairments in Parkinson’s Disease: A Survey Among 320 Healthcare Professionals10
Inflammasome Activation in Parkinson’s Disease10
Life with Parkinson’s Disease During the COVID-19 Pandemic: The Pressure Is “OFF”10
Respiratory Disorders in Parkinson’s Disease10
Heart Rate Changes Prior to Freezing of Gait Episodes Are Related to Anxiety9
Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity9
Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease9
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression9
Parkinson’s Disease Cognitive Phenotypes Show Unique Clock Drawing Features when Measured with Digital Technology9
Autonomic and Depression Symptoms in Parkinson’s Disease: Clinical Evidence for Overlapping Physiology9
Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease9
Hemispheric Network Expression in Parkinson’s Disease: Relationship to Dopaminergic Asymmetries9
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease9
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel9
The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy9
Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson’s Disease?9
Association Between Thyroid Diseases and Parkinson’s Disease: A Nested Case-Control Study Using a National Health Screening Cohort9
Is there a Neurobiological Rationale for the Utility of the Iowa Gambling Task in Parkinson’s Disease?9
Mild Parkinsonian Signs in a Community Ambulant Population9
Introducing the Parkinson’s KinetiGraph into Routine Parkinson’s Disease Care: A 3-Year Single Centre Experience9
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson’s Disease9
BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia9
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling9
Structural and Functional Correlates of Hallucinations and Illusions in Parkinson’s Disease9
Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex9
0.040989875793457